No profile data available.
Myriad Genetics, Inc. (MYGN) is a healthcare company in the DNA testing equipment industry, based in Salt Lake City, United States, with about 2,700 full-time employees.
It reported revenue of $824.50 million for fiscal year 2025, down 1.6% from fiscal year 2024, and net income of -$365.90 million. United States was its largest region in fiscal year 2025, with 93% of revenue. Its market capitalization was $412.25 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Myriad Genetics reported $824.50 million in revenue for fiscal year 2025, down 1.6% from $837.60 million in fiscal year 2024.
United States: 93% of revenue by region in fiscal year 2025, followed by Rest of world (7%).
$412.25 million as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Veracyte, Inc. (VCYT), CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Burning Rock Biotech Limited (BNR).